Loading...
XSHE002864
Market cap391mUSD
Jan 08, Last price  
27.37CNY
1D
-5.82%
1Q
2.13%
IPO
72.36%
Name

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

Chart & Performance

D1W1MN
XSHE:002864 chart
P/E
25.97
P/S
2.92
EPS
1.05
Div Yield, %
0.85%
Shrs. gr., 5y
2.53%
Rev. gr., 5y
14.92%
Revenues
981m
+0.67%
226,614,469245,695,161256,097,405305,425,505376,791,557489,447,811610,636,793670,312,981887,484,877974,293,135980,828,104
Net income
110m
+9.16%
32,894,42640,072,40342,638,23139,527,73643,718,97564,681,88471,778,89679,115,00193,169,906101,163,536110,432,177
CFO
104m
-17.00%
25,433,84148,555,47540,620,72961,991,43628,449,11346,846,10667,886,53192,238,027116,035,587125,362,160104,047,784
Dividend
Jun 03, 20240.22 CNY/sh
Earnings
May 21, 2025

Profile

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells drugs and GAP cultivation of medicinal materials in China. It offers orthopedic, cardio-cerebrovascular, digestive, supplement category, respiratory, Chinese anti-inflammatory, pediatric, gynecology, hepatobiliary, and specialty drugs. The company was founded in 1997 and is headquartered in Xi'an, China.
URL
http://www.pljt.com/
IPO date
Nov 16, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
980,828
0.67%
974,293
9.78%
Cost of revenue
779,600
805,305
Unusual Expense (Income)
NOPBT
201,229
168,988
NOPBT Margin
20.52%
17.34%
Operating Taxes
17,704
16,033
Tax Rate
8.80%
9.49%
NOPAT
183,525
152,955
Net income
110,432
9.16%
101,164
8.58%
Dividends
(24,298)
(15,398)
Dividend yield
0.65%
0.43%
Proceeds from repurchase of equity
(56)
BB yield
0.00%
Debt
Debt current
100,000
366,027
Long-term debt
4,215
28,001
Deferred revenue
91,246
52,830
Other long-term liabilities
(1)
Net debt
(1,007,509)
(451,077)
Cash flow
Cash from operating activities
104,048
125,362
CAPEX
(62,513)
Cash from investing activities
(62,410)
Cash from financing activities
236,931
316,347
FCF
71,052
117,010
Balance
Cash
1,102,013
823,444
Long term investments
9,711
21,661
Excess cash
1,062,682
796,390
Stockholders' equity
682,891
704,940
Invested Capital
1,061,722
656,918
ROIC
21.36%
25.73%
ROCE
11.53%
12.41%
EV
Common stock shares outstanding
97,728
93,381
Price
38.49
-0.77%
38.79
23.81%
Market cap
3,761,535
3.84%
3,622,266
35.16%
EV
2,756,240
3,189,142
EBITDA
232,268
187,295
EV/EBITDA
11.87
17.03
Interest
6,230
13,915
Interest/NOPBT
3.10%
8.23%